# 60 Degrees Pharmaceuticals, Inc.

**SXTPW**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001946563

# None

**No letter**

5 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.76 AUC<br>filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| **Peer failure rate** | 0.60% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | under $12.5M assets<br>total assets $5.4M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | short runway, thin data; fortress balan...<br>not computable: dilution, distress |
| **Inputs computable** | 5 of 14 |
| **Graded from** | filings received through Mar 30, 2026<br>223 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026 |
| **Last close** | $0.06<br>2026-02-09; market equity $0; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 30, 2026*

We are a specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda, a malaria preventative treatment that has been on the market since late 2019.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 76.4** | | | | | | |
| Gross profitability | 4.2% | 32.3% | | 86.1 | 365 | 2025-12-31 |
| Return on invested capital | (335.2%) | 9.3% | | 99.3 | 74 | 2025-12-31 |
| Accruals ratio | (9.3%) | (6.6%) | | 43.6 | 802 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 3* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| **Solvency, sleeve percentile 71.8** | | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | | |
| Altman Z double-prime | (33.25) | (0.37) | | 82.9 | 747 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *EBITDA must exceed $100,000* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 2.66x | 2.94x | | 60.6 | 828 | 2025-12-31 |
| **Growth and financing** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.0% | | | | |
| *four annual observations are required; found 3* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *four consecutive annual FCF observations are required; found 3* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *NOPAT must exceed $100,000* | | | | | | |
| Asset growth, three years | not computable | 2.2% | | | | |
| *four annual observations are required; found 3* | | | | | | |
| Net share issuance, one year | not computable | 2.5% | | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | | |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 1.4 months |
| Thin data | 5 of 14 grade factors are computable; minimum is 7 |
| Fortress balance sheet | cash minus debt is 1,360,065 USD; Altman Z is not used |

## What the price implies

*at the 2026-02-09 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (53.3%) | (2.1%) | 14 |
| Distance from 52-week high | (65.8%) | (30.5%) | 16 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | not computable | (1.0%) | |
| Book value to price | not computable | 0.29 | |
| Sales to price | not computable | 0.30 | |
| Composite equity issuance, five years | not computable | 21.4% | |
| Relative strength against the sector, log excess return | (0.93) | (0.19) | 14 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Asset turnover improved | pass |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $1.0M |
| Operating cash flow, four quarters | -$8.8M |
| Months of runway | 1.4 |
| Days since last periodic filing | 86 (10-Q received Aug 14, 2026) |
| Median daily dollar volume, 63 sessions | $15 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $223,776 | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 2 | assets | us-gaap:Assets | $5.4M | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 3 | operating income | us-gaap:OperatingIncomeLoss | -$7.8M | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 4 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$7.4M | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 5 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 6 | total debt | us-gaap:LongTermDebt | $150,000 | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 7 | book equity | us-gaap:StockholdersEquity | $3.5M | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 8 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $1.5M | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 9 | total debt | us-gaap:LongTermDebt | $150,000 | 2024-12-31 | 2025-03-27 | 10-K | 25-003343 |
| 10 | book equity | us-gaap:StockholdersEquity | $4.0M | 2024-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 11 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $1.7M | 2024-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 12 | net income | us-gaap:NetIncomeLoss | -$7.4M | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 13 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$6.8M | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 14 | assets | us-gaap:Assets | $5.8M | 2024-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 15 | current assets | us-gaap:AssetsCurrent | $4.9M | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $1.8M | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 17 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$47.9M | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 18 | liabilities | us-gaap:Liabilities | $2.0M | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 19 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $43,324 | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 20 | operating income | us-gaap:OperatingIncomeLoss | -$5.2M | 2023-12-31 | 2025-03-27 | 10-K | 25-003343 |
| 21 | interest expense | us-gaap:InterestExpense | $2.3M | 2023-12-31 | 2024-04-01 | 10-K | 24-028577 |
| 22 | revenue | us-gaap:Revenues | $1.0M | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 23 | revenue | us-gaap:Revenues | $607,574 | 2024-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 24 | revenue | us-gaap:Revenues | $253,573 | 2023-12-31 | 2025-03-27 | 10-K | 25-003343 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $139,881 | 2025-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 26 | current assets | us-gaap:AssetsCurrent | $5.4M | 2024-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 27 | current liabilities | us-gaap:LiabilitiesCurrent | $1.7M | 2024-12-31 | 2026-03-30 | 10-K | 26-000467 |
| 28 | assets | us-gaap:Assets | $7.8M | 2023-12-31 | 2025-03-27 | 10-K | 25-003343 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.